Carannante Novella, Pallotto Carlo, Bernardo Mariano, Di Caprio Giovanni, Tascini Carlo
a First division of Infectious Diseases , Cotugno Hospital, AORN dei Colli , Naples , Italy.
b Infectious Diseases Section, Department of Medicine , University of Perugia , Perugia , Italy.
J Chemother. 2018 May;30(3):183-184. doi: 10.1080/1120009X.2018.1424504. Epub 2018 Jan 16.
KPC-producing Klebsiella pneumoniae (KPC-Kp) is nowadays a global concern. Ceftazidime/avibactam is the most promising novel antibiotic combination available at the moment. We describe the case of a migrant with no risk factors for an infection due to multidrug resistant bacteria. He suffered from a KPC-Kp cellulitis and was treated with a ceftazidime/avibactam-meropenem-fosfomycin combination that not only eradicated the infection but also decontaminated his gut. Ceftazidime/avibactam-based treatment can be useful also in decontamination procedures.
产KPC的肺炎克雷伯菌(KPC-Kp)如今已成为全球关注的问题。头孢他啶/阿维巴坦是目前最有前景的新型抗生素组合。我们描述了一例没有多重耐药菌感染风险因素的移民病例。他患有KPC-Kp蜂窝织炎,接受了头孢他啶/阿维巴坦-美罗培南-磷霉素联合治疗,该联合治疗不仅根除了感染,还对他的肠道进行了去污染处理。基于头孢他啶/阿维巴坦的治疗在去污染程序中也可能有用。